(Q33851131)

29 July 2017

1 reference

title

A critical analysis of the use of p53 as a marker for management of bladder cancer (English)

1 reference

29 July 2017

Olumi AF

1

1 reference

29 July 2017

1 February 2000

1 reference

Urologic Clinics of North America

29 July 2017

1 reference

29 July 2017

27

1 reference

29 July 2017

75-82, ix

1 reference

29 July 2017

1

1 reference

Bax. The pro-apoptotic Bcl-2 family member, Bax.

29 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970236-6

7 January 2021

p53 and treatment of bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970236-6

7 January 2021

Mechanisms of p53-mediated apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970236-6

7 January 2021

Regulation of p53 downstream genes.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970236-6

7 January 2021

Accumulation of nuclear p53 and tumor progression in bladder cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970236-6

7 January 2021

Relationship of p53 and bcl-2 to prognosis in muscle-invasive transitional cell carcinoma of the bladder

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970236-6

7 January 2021

Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970236-6

7 January 2021

Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970236-6

7 January 2021

Mdm2 promotes the rapid degradation of p53

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970236-6

7 January 2021

Can p53 help select patients with invasive bladder cancer for bladder preservation?

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970236-6

7 January 2021

Bacillus Calmette-Guérin therapy alters the progression of superficial bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970236-6

7 January 2021

Bacillus Calmette-Guerin therapy for superficial bladder cancer: a 10-year followup

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970236-6

7 January 2021

Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970236-6

7 January 2021

Brief report: molecular biology and the early detection of carcinoma of the bladder--the case of Hubert H. Humphrey

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970236-6

7 January 2021

Significance of p53 overexpression in urinary bladder transitional cell carcinoma in situ before and after bacillus Calmette-Guérin treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970236-6

7 January 2021

Predictive value of p53 and pRb immunostaining in locally advanced bladder cancer treated with cystectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970236-6

7 January 2021

The emerging p53 gene family

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970236-6

7 January 2021

Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970236-6

7 January 2021

Absence of p53 overexpression and favorable response to cisplatin-based neoadjuvant chemotherapy in urothelial carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970236-6

7 January 2021

Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970236-6

7 January 2021

Results of 6 Weekly Intravesical Bacillus Calmette-Guerin Instillations on the Treatment of Superficial Bladder Tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970236-6

7 January 2021

ONCOGENESIS: Landscaping the Cancer Terrain

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970236-6

7 January 2021

The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970236-6

7 January 2021

Regulation of p53 stability by Mdm2

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970236-6

7 January 2021

Overexpression of p53 protein in a high-risk population of patients with superficial bladder cancer before and after bacillus Calmette-Guérin therapy: correlation to clinical outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970236-6

7 January 2021

Cancer statistics, 1999.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970236-6

7 January 2021

Correlation between p53 over expression and response to bacillus Calmette-Guerin therapy in a high risk select population of patients with T1G3 bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970236-6

7 January 2021

p53-dependent apoptosis modulates the cytotoxicity of anticancer agents

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970236-6

7 January 2021

Genomic organization and mutation analysis of p73 in oligodendrogliomas with chromosome 1 p-arm deletions

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970236-6

7 January 2021

Analysis of early failures after intravesical instillation therapy with bacille Calmette-Guérin for carcinoma in situ of the bladder

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970236-6

7 January 2021

Cloning and functional analysis of human p51, which structurally and functionally resembles p53

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970236-6

7 January 2021

Long-term efficacy of intravesical bacillus Calmette-Guerin for carcinoma in situ: relationship of progression to histological response and p53 nuclear accumulation

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970236-6

7 January 2021

Intravesical Bacillus Calmette-Guérin with the Danish strain for treatment of carcinoma in situ of the bladder.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970236-6

7 January 2021

p53 status does not predict initial clinical response to bacillus Calmette-Guerin intravesical therapy in T1 bladder tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970236-6

7 January 2021

p53 mutations in bladder tumors inactivate the transactivation of the p21 and Bax genes, and have a predictive value for the clinical outcome after bacillus Calmette-Guerin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970236-6

7 January 2021

The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970236-6

7 January 2021

P53 accumulation, deoxyribonucleic acid ploidy and progression of bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970236-6

7 January 2021

Does p53 immunostaining improve diagnostic accuracy in urine cytology?

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970236-6

7 January 2021

Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970236-6

7 January 2021

Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970236-6

7 January 2021

A novel protein with strong homology to the tumor suppressor p53.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970236-6

7 January 2021

p53 nuclear immunoreactivity as a predictor of response and outcome following chemotherapy for metastatic bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970236-6

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970236-6

7 January 2021

Clinical significance of mdm2 and p53 expression in bladder cancer. A comparison with cell proliferation and apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970236-6

7 January 2021

Identification of p53 gene mutations in bladder cancers and urine samples

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970236-6

7 January 2021

Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970236-6

7 January 2021

The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970236-6

7 January 2021

Diagnosis of bladder cancer by analysis of the allelic loss of the p53 gene in urine samples using blunt-end single-strand conformation polymorphism

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970236-6

7 January 2021

A new human p53 homologue

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970236-6

7 January 2021

The prognostic value of p53 in superficially infiltrating transitional cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970236-6

7 January 2021

p53 mutations have no additional prognostic value over stage in bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970236-6

7 January 2021

Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970236-6

7 January 2021

Prognostic value of p53 in muscle-invasive bladder cancer treated with preoperative radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970236-6

7 January 2021

p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970236-6

7 January 2021

Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L)

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970236-6

7 January 2021

ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970236-6

7 January 2021

10.1016/S0094-0143(05)70236-6

Identifiers

DOI

1 reference

29 July 2017

1 reference

PubMed ID

10696247